Duality Advisers, LP Editas Medicine, Inc. Transaction History

Duality Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$14.08 - $27.63 $317,447 - $622,945	-22,546 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$26.55 - $40.57 $530,309 - $810,345	-19,974 Reduced 46.98%	22,546 $599,000
Q3 2021 Nov 08, 2021	BUY	$39.27 - $72.94 $1.67 Million - $3.1 Million	42,520 New	42,520 $1.75 Million
Q4 2020 Feb 09, 2021	SELL	$27.07 - $84.35 $662,132 - $2.06 Million	-24,460 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$28.06 - $37.16 $686,347 - $908,933	24,460 New	24,460 $686,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.